| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
25,618 |
19,789 |
$716K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
15,699 |
12,432 |
$612K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
650 |
580 |
$43K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
477 |
401 |
$28K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
293 |
255 |
$17K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
144 |
134 |
$10K |
| G0511 |
Rural health clinic or federally qualified health center (rhc or fqhc) only, general care management, 20 minutes or more of clinical staff time for chronic care management services or behavioral health integration services directed by an rhc or fqhc practitioner (physician, np, pa, or cnm), per calendar month |
737 |
656 |
$8K |
| 99401 |
|
506 |
391 |
$8K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
502 |
423 |
$4K |
| G0447 |
Face-to-face behavioral counseling for obesity, 15 minutes |
585 |
374 |
$4K |
| 99308 |
Subsequent nursing facility care, per day, straightforward |
94 |
92 |
$3K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
118 |
83 |
$2K |
| 99406 |
|
347 |
239 |
$2K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
25 |
24 |
$2K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
79 |
69 |
$2K |
| 96160 |
|
310 |
229 |
$2K |
| 96127 |
|
422 |
380 |
$1K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
166 |
134 |
$1K |
| G2025 |
Payment for a telehealth distant site service furnished by a rural health clinic (rhc) or federally qualified health center (fqhc) only |
45 |
42 |
$1K |
| 92551 |
|
147 |
123 |
$1K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
50 |
41 |
$854.69 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
16 |
14 |
$550.11 |
| 1159F |
|
2,205 |
1,903 |
$290.01 |
| 99173 |
|
12 |
12 |
$188.00 |
| 3074F |
|
4,459 |
3,680 |
$182.85 |
| 3078F |
|
3,848 |
3,175 |
$182.23 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
19 |
12 |
$176.31 |
| 3079F |
|
1,761 |
1,517 |
$161.98 |
| 3008F |
|
16,080 |
12,596 |
$110.20 |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
14 |
13 |
$64.00 |
| 3075F |
|
557 |
480 |
$51.04 |
| 3077F |
|
591 |
507 |
$50.00 |
| 3080F |
|
149 |
133 |
$10.00 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
50 |
41 |
$4.72 |
| 81003 |
|
29 |
26 |
$2.77 |
| 3061F |
|
2,563 |
1,946 |
$0.00 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
138 |
108 |
$0.00 |
| 4010F |
|
191 |
155 |
$0.00 |
| 1160F |
|
1,620 |
1,435 |
$0.00 |
| G8431 |
Screening for depression is documented as being positive and a follow-up plan is documented |
59 |
53 |
$0.00 |